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Myelofibrotic transformation is a well-recognized complication of essential 
thrombocythemia (ET) and polycythemia vera (PV)(1, 2). However, there is scarce 
information on life expectancy and prognostic factors of patients developing this 
complication (1, 3-5). Prognostic models devised for primary myelofibrosis (PMF) are 
used to drive treatment decisions in patients with post-ET/PV MF, despite the lack of 
studies validating the prediction accuracy of such stratification models in this setting. 
Our aim was to evaluate the performance of the most widely used prognostic model in 
PMF, i.e. the International Prognostic Scoring System (IPSS)(6), in a nationwide series 
of patients with post-ET/PV MF.  
 Data from 176 patients diagnosed with post-ET (n=115) or post-PV (n=61) MF 
in 39 Spanish institutions during January/2000-May/2013 were retrospectively 
analyzed. Diagnosis was made according to the criteria in use at the time of first 
observation. Treatment for MF included hydroxycarbamide (n=100) or other 
cytoreductive therapy (n=25), erythropoiesis-stimulating agents (n=45), JAK inhibitors 
(n=45), danazol (n=12), immunomodulators (n=12), splenectomy (n=3), splenic 
irradiation (n=7), and allogeneic transplantation (n=11). Variables taken at MF 
diagnosis and analyzed for their predictive value on outcomes were sex, previous 
myeloproliferative neoplasm, splenomegaly, IPSS risk category, each individual factor 
of the IPSS, thrombocytopenia, JAK2 status, cytogenetics (7), and whether or not the 
patient was on cytoreductive therapy at MF diagnosis. Multivariate analysis of factors 
predicting survival was performed by the Cox regression method. Cumulative incidence 
of acute myeloid leukemia (AML) or AML-unrelated death was analyzed in the 
framework of competing risks. Multivariate analyses of factors predicting each of the 
above competing outcomes were performed by the Fine and Gray method (8). Log-rank 
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test was used to compare Kaplan-Meier curves. P<0.05 was considered statistically 
significant.  
  Table 1 shows the patients' characteristics at MF presentation. Median time 
from original diagnosis to myelofibrosis was 8.6 years for post-ET MF and 9.8 years for 
post-PV MF. With a median follow-up from post-ET/PV MF diagnosis of 1.8 years, 50 
(29%) patients had died, 5 (3%) were lost to follow-up and the remaining were censored 
alive. Median survival was 8.6 years. Causes of death included progression of MF 
without AML (n=18), AML (n=11), cardiovascular complications (n=7), transplant-
related complications (n=4), infection (n=3), bleeding (n=2), a second malignancy 
(n=1), or were unknown (n=4).  
 According to the IPSS, 13% patients were in the low-risk group; 29% in the 
intermediate-1; 31% in the intermediate-2; and 27% in the high-risk category, and their 
median survivals were, respectively, not yet reached, 10, 8.5, and 3.1 years. There was 
no statistically significant difference in survival between the low-risk and the 
intermediate-1 categories, and between the latter and the intermediate-2, whereas the 
high-risk group had a significant poorer survival than the intermediate-2 
(P=0.008)(Figure 1). 
Among factors included in the IPSS, older age, anemia, and circulating blasts 
retained a univariate association with shorter survival, whereas constitutional symptoms 
and leukocytosis lacked prognostic value. There was no significant difference in 
survival between patients with a prior diagnosis of PV or ET. The best predictive model 
for shorter survival included the following independent variables: age >65 years 
(Hazard ratio [HR]=3.6; 95% Confidence Interval [CI]:1.8-7.3; P<0.001); Hb <10 g/dL 
(HR=2.6; 95%CI:1.4-4.6; P=0.002); platelets <100 x 109/L (HR=3.5; 95%CI:1.7-7.3; 
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P=0.001); and being on hydroxycarbamide at MF diagnosis (HR=2.7; 95%CI:1.5-5.9; 
P=0.002).  
 Progression to AML occurred in 12 (6.8%) patients over an observation period 
of 509 patient-years, what accounts for an incidence rate of 2.3 cases per 100 patient-
years. Thrombocytopenia <100 x 109/L was the only predictor for progression to AML 
(HR=5.45; 95%CI:1.51-19.6; P=0.01), whereas age >65 years (HR=2.58; 95%CI:1.20-
5.55; P=0.01), anemia (HR=2.45; 95%CI:1.22-4.92; P=0.01), and being on 
hydroxycarbamide at myelofibrotic transformation (HR=1.96; 95%CI:0.98-3.90; 
P=0.05), were associated with AML-unrelated death.  
 We presume that the lack of prognostic significance of some variables of the 
IPSS may be due to the effect of the cytoreductive treatment that many patients were 
receiving at the time of myelofibrotic transformation for the management of ET or PV. 
This situation differs from that of PMF patients, in whom the risk factors at disease 
diagnosis are usually computed without any myelosuppressive treatment. Other factors 
could have also influenced on our findings. Thus, 39% of patients with constitutional 
symptoms received JAK inhibitors, whereas this treatment was used in only 19% of 
those without such symptoms at MF diagnosis. Ruxolitinib has been associated with a 
reduction in the risk of death compared to conventional therapy (9), which could 
presumably have blunted the poor prognosis associated with this feature.  
In line with our results, in an Italian series (4) of 68 patients with post-PV MF, 
anemia was the only predictor for survival at disease presentation, whereas age and 
leukocyte count lacked prognostic significance. In 66 young patients with post-ET/PV 
MF from the Mayo Clinic (3), anemia was again an independent risk factor for 
shortened survival, although the strongest adverse factor was the unfavorable 
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cytogenetics. Neither constitutional symptoms nor the leukocyte count predicted for 
survival.  
 By multivariate analysis, two variables not included in the IPSS, namely 
thrombocytopenia and hydroxycarbamide treatment at myelofibrotic transformation, 
were shown to correlate with survival. The former has been identified as a poor 
prognostic factor in PMF (10, 11) and post-PV MF (4). Low platelets are often 
associated with anemia, making it difficult to qualify thrombocytopenia as an 
independent prognostic factor, which was the reason why this variable was excluded 
from the IPSS (6). In our study, thrombocytopenia was an independent predictor for 
shorter survival probably because it was associated with a higher risk of AML. Such an 
association has also been reported in PMF (10-13). With regard to the poor prognostic 
significance of being on hydroxycarbamide at MF diagnosis, we think that some kind of 
selection bias may be operating here. Indeed, hydroxycarbamide is usually indicated in 
older patients and in those with more marked myeloproliferative features, what may 
have contributed to blur the prognostic significance of such features.  
 In conclusion, the results from the present study indicate that the IPSS fails to 
accurately discriminate different prognostic groups in post-ET/PV MF. An alternative 
tool is therefore required for patients’ risk stratification to help physicians on 
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Table 1. Demographic and baseline clinical characteristics of patients at diagnosis of 
post-ET and post-PV MF 
Characteristic All patients (n = 176) 
Post-ET MF 
(n = 115) 
Post-PV MF 
(n= 61) 
Age, years* 65 (23 - 88) 64 (23 - 88) 68 (39 - 84) 
   >65 95 (54%) 55 (48%) 40 (66%) 
Sex, male/female 83 / 93 50 / 65 33 / 28 
Constitutional symptoms 54 (31%) 33 (29%) 21 (34%) 
Palpable splenomegaly 129 (73%) 75 (65%) 54 (86%) 
Hb, g/dL* 10.7 (4.5 - 17.7) 10.5 (4.5 - 15.4) 11.1 (7.3 - 17.7) 
   <10 57 (33%) 42 (37%) 15 (25%) 
WBC, x109/L* 9.9 (0.3 - 77) 8.7 (0.3 - 77) 10.9 (2.4 - 60) 
   >25 23 (14%) 15 (14%) 8 (14%) 
Platelets, x109/L* 364 (5 - 1564) 427 (5 - 1564) 289 (35 - 1368) 
   <50 8 (5%) 7 (6%) 1 (2%) 
   <100 18 (11%) 11 (10%) 7 (12%) 
Blood blasts >1% 80 (48%) 55 (51%) 25 (42%) 
Abnormal karyotype 24/94 (26%) 16/66 (24%) 8/28 (29%) 
   Unfavorable abnormalities† 8% 6% 11% 
JAK2 mutation‡ 80/124 (64%) 37/77 (48%) 43/47 (91%) 
IPSS risk group§    
   Low 22 (13%) 16 (15%) 6 (10%) 
   Intermediate-1 48 (29%) 28 (26%) 20 (35%) 
   Intermediate-2 51 (31%) 36 (33%) 15 (26%) 
   High 45 (27%) 28 (26%) 17 (29%) 
 
Abbreviations: ET, essential thrombocythemia; PV, polycythemia vera; MF, 
myelofibrosis; IPSS, International Prognostic Scoring System 
* Median (range) 
†
 +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), 11q23 rearrangement or complex karyotype  
‡ These figures represent the JAK2 V617F mutated cases, since the exon 12 mutations 
were not studied in most institutions 
§ In 166 evaluable patients 
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LEGEND FOR THE FIGURE 
 
Fig 1. Survival after diagnosis of post-ET/PV myelofibrosis according to the IPSS risk 
category. 
 
 
 
 
 
 
 
 

